Pluristem’s successful stem cell trial last week on muscle injuries is an important first step for the company, says the company’s CEO Zami Aberman. By using placental cells, Pluristem eliminates the ethical issues surrounding where the cells are derived, according to Aberman, who also touts his company’s unique ability to manufacture 3D cells. Aberman is also bullish on Pluristem’s partnership with United Therapeutics, another biotech company that has seen its shares spike in the past year.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
